Skip to content

A randomized, active-controlled trial of prophylactic treatment of seasonal allergic rhinitis with azostine hydrochloride and fluticasone propionate nasal spray

A randomized, single-Blinded, controlled trial of prophylactic treatment of seasonal allergic rhinitis with azostine hydrochloride and fluticasone propionate nasal spray

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073758
Enrollment
Unknown
Registered
2023-07-20
Start date
2023-07-16
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

seasonal allergic rhinitis

Interventions

prophylactic treatment group:Starting using nasal spray 2 weeks ahead of the autumn pollen season
general treatment group:Start using nasal spray when nasal symptoms occur in autumn pollen season

Sponsors

Yulin No.2 hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Male or female aged 12 and above; (2) Allergic rhinitis was diagnosed through typical clinical symptoms (repeated sneezing, runny nose, stuffy nose or itchy nose) and signs, and the symptoms mainly occurred in autumn; (3) The allergen test results meet the following standards: 1) Weed pollen serum sIgE = Grade II or skin test = "++"; 2) The result of serum sIgE or skin test of dust mite, mold and pet is negative.

Exclusion criteria

Exclusion criteria: (1) Individuals who have received or are currently undergoing any allergen specific immunotherapy; (2) Individuals who have been receiving anti IgE monoclonal antibodies or anti IL4/IL13 monoclonal antibodies in the past six months or currently; (3) Individuals with malignant tumors; (4) Pregnant or lactating individuals; (5) Individuals with other serious liver, kidney, heart, hematopoietic, neurological, or mental illnesses; (6) Other situations that the researcher deems unsuitable for inclusion.

Design outcomes

Primary

MeasureTime frame
TNSS;the proportion of minimal symptom days;

Secondary

MeasureTime frame
Rate of acute attack of asthma;Pulmonary function;

Countries

China

Contacts

Public ContactNa Gao

Yulin No.2 hospital

superfine@126.com+86 153 1142 3682

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026